

Medicines and Poisons Act 2019

Extended Practice Authority 'Pharmacists – Community pharmacy chronic conditions management pilot'



Queensland Government

Version control

Version	Replaces version	Date approved	Commencement date
1	N/A	16 May 2025	1 July 2025

Disclaimer: Please note that any material printed is regarded as an uncontrolled copy. It is the responsibility of the person printing the document to refer frequently to <https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines-poisons-act/legislation-standards> for updates

Extended Practice Authority - 'Community pharmacy chronic conditions management pilot'

This extended practice authority (EPA) has been made by the Director-General, Queensland Health, as the chief executive under section 232 of the *Medicines and Poisons Act 2019* (Qld). It states the scope of the regulated activities with the regulated substances which a participating pharmacist is authorised to carry out for the purposes described in the table under Schedule 9, Part 1, Division 2A of the Medicines and Poisons (Medicines) Regulation 2021 (Qld).

A term used in this EPA that is defined in the *Medicines and Poisons Act 2019* or the Medicines and Poisons (Medicines) Regulation 2021, has the meaning stated in the *Medicines and Poisons Act 2019* or Medicines and Poisons (Medicines) Regulation 2021.

Part 1. Circumstances and conditions

- 1.1 A participating pharmacist must meet the requirements specified within the 'Queensland Community Pharmacy Chronic Conditions Management Pilot – Participation Requirements' to prescribe a medicine under this EPA.
- 1.2 A participating pharmacist may only prescribe a medicine under this EPA in a participating pharmacy that meets the requirements specified within the 'Queensland Community Pharmacy Chronic Conditions Management Pilot – Participation Requirements'.
- 1.3 A participating pharmacist must not prescribe a medicine for the treatment of an animal under this EPA.
- 1.4 A participating pharmacist must, when prescribing a medicine under this EPA, document consent obtained from the patient to have a service provided under this EPA, including evaluation, financial, and clinical consent.

Part 2. Prescribing

- 2.1 A participating pharmacist may prescribe a medicine listed in Appendix 1, Column 1:
 - 2.1.1 for the indication listed in Appendix 1, Column 2; and
 - 2.1.2 subject to the restrictions stated opposite in Appendix 1, Column 3; and
 - 2.1.3 the participating pharmacist must take all reasonable steps to prescribe the medicine in accordance with the current online version of the section/s of the Therapeutic Guidelines specified within Appendix 1, Column 3.
- 2.2 A participating pharmacist must, when prescribing a medicine under this EPA, document the following in the clinical record of a consultation with a patient:
 - 2.2.1 Relevant patient history; and
 - 2.2.2 An assessment of the condition that requires the prescribed medicine; and
 - 2.2.3 The management plan for treating the patient's condition including:
 - a. The name of the medicine prescribed; and
 - b. The strength of the medicine prescribed; and

- c. The formulation of the medicine prescribed; and
 - d. The instructions for use of the medicine prescribed; and
 - e. The amount of the medicine prescribed.
- 2.3 When prescribing a medicine, the pharmacist must make a written prescription that is compliant with Chapter 4, Part 6, Division 3 of the Medicines and Poisons (Medicines) Regulation 2021.
- 2.4 The pharmacist must not prescribe, in one prescription, greater than 12 months' supply of a medicine listed in Appendix 1 of this EPA.

Appendix 1 - Medicines for the community pharmacy chronic conditions management pilot

Medicines for the Community Pharmacy Chronic Conditions Management Pilot		
Column 1 - Regulated substance	Column 2 – Indication	Column 3 - Restrictions/Conditions
Inhaled anticholinergics Inhaled beta-2 agonists Inhaled corticosteroids Montelukast Prednisolone Prednisone	Asthma – management of asthma symptoms	<ul style="list-style-type: none"> The prescriber must take all reasonable steps to prescribe the medicine in accordance with the current online version of the section of the Therapeutic Guidelines titled '<i>Respiratory: Asthma</i>'. The medicine may only be prescribed to a patient aged 16 years to 65 years.
Angiotensin converting enzyme (ACE) inhibitors Angiotensin II receptor blockers Dihydropyridine calcium channel blockers Thiazides and thiazide-like diuretics	Cardiovascular disease risk reduction – management of hypertension and blood pressure reduction	<ul style="list-style-type: none"> The prescriber must take all reasonable steps to prescribe the medicine in accordance with the current online version of the section of the Therapeutic Guidelines titled '<i>Cardiovascular: Blood pressure reduction: Hypertension and blood pressure reduction</i>'. The medicine may only be prescribed to a patient aged 18 years to 79 years.
Ezetimibe HMG-CoA reductase inhibitors (Statins) Fibrates	Cardiovascular disease risk reduction – lipid modification	<ul style="list-style-type: none"> The prescriber must take all reasonable steps to prescribe the medicine in accordance with the current online version of the section of the Therapeutic Guidelines titled '<i>Cardiovascular: Lipid modification</i>'. The medicine may only be prescribed to a patient aged 18 years to 79 years.
Dipeptidyl peptidase 4 (DPP-4) inhibitors Glucagon-like peptide-1 (GLP-1) analogues Metformin Sodium-glucose co-transporter 2 (SLGT2) inhibitors	Cardiovascular disease risk reduction – management of blood glucose	<ul style="list-style-type: none"> The prescriber must take all reasonable steps to prescribe the medicine in accordance with the current online version of the section of the Therapeutic Guidelines titled '<i>Diabetes: Type 2 diabetes in adults</i>'. The medicine may only be prescribed to a patient aged 18 years to 79 years.
Inhaled anticholinergics Inhaled beta-2 agonists Inhaled corticosteroids Prednisolone Prednisone	Chronic obstructive pulmonary disease	<ul style="list-style-type: none"> The prescriber must take all reasonable steps to prescribe the medicine in accordance with the current online version of the section of the Therapeutic Guidelines titled '<i>Respiratory: Chronic obstructive pulmonary disease</i>'. The medicine may only be prescribed to a patient aged 35 years and older.